Can a transplant drug stop HHT nosebleeds? small study tests sirolimus
NCT ID NCT05269849
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small pilot study tested the safety and effectiveness of the oral drug sirolimus for reducing nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). Ten adults with moderate to severe nosebleeds took 2 mg of sirolimus daily for 3 months. Researchers tracked bleeding duration, side effects, and lab values to see if the drug could help control this common HHT symptom.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPISTAXIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Michael's Hospital
Toronto, Ontario, M5B 1W8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill to stop the bleeding? new hope for HHT nosebleeds
- Massive HHT registry aims to unlock secrets of rare bleeding disorder
- Blood thinners in HHT: a risky balancing act under the microscope
- New ointment could tame HHT nosebleeds
- New antibody aims to tame rare bleeding disorder
- New drug aims to stop nosebleeds in rare blood vessel disorder